Device Trial Radar · NCT06506903
Avalus Ultra Post-Approval Study (PAS)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
190
Actual
Start
Nov 20, 2024
Primary completion
Nov 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Medtronic Cardiac SurgeryPublic (MDT)
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.
Conditions
- Aortic Valve Disease
Interventions
Medtronic Avalus UltraDevice
Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-related incidence of adverse events and death through 1 year post-procedureTime frame: 30 days and 1 year post-procedure
- Evaluation of Mean Pressure Gradient (mmHg) through 1 year post-procedureTime frame: 30 days and 1 year post-procedure
- Evaluation of Effective Orifice Area (cm^2) through 1 year post-procedureTime frame: 30 days and 1 year post-procedure
3 more outcomes with a free account
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Hartford Hospital
Hartford, Connecticut
University of Florida Shands
Gainesville, Florida
Emory Saint Joseph's
Atlanta, Georgia
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.